Articles | Volume 7, issue 5
https://doi.org/10.5194/jbji-7-187-2022
© Author(s) 2022. This work is distributed under
the Creative Commons Attribution 4.0 License.
the Creative Commons Attribution 4.0 License.
https://doi.org/10.5194/jbji-7-187-2022
© Author(s) 2022. This work is distributed under
the Creative Commons Attribution 4.0 License.
the Creative Commons Attribution 4.0 License.
Lysins – a new armamentarium for the treatment of bone and joint infections?
Parham Sendi
CORRESPONDING AUTHOR
Institute for Infectious Diseases, University of Bern, Bern,
Switzerland
JBJI Editor-in-chief
Tristan Ferry
Hospices Civils de Lyon, 69004 Lyon, France
Université Claude Bernard Lyon 1, 69100 Villeurbanne, France
Centre de Références des IOA Complexes de Lyon, CRIOAc Lyon,
69004 Lyon, France
StaPath Team, Centre International de Recherche en Infectiologie,
CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, 69008 Lyon, France
Related authors
Said El Zein, Elie F. Berbari, Allison M. LeMahieu, Anil Jagtiani, Parham Sendi, Abinash Virk, Mark E. Morrey, and Aaron J. Tande
J. Bone Joint Infect., 9, 107–115, https://doi.org/10.5194/jbji-9-107-2024, https://doi.org/10.5194/jbji-9-107-2024, 2024
Short summary
Short summary
Our study investigated olecranon septic bursitis treatment, focusing on postsurgical antibiotic use. Analyzing 22 years of Mayo Clinic data, we found that smoking and not administering antibiotics following surgery led to poorer outcomes. A 3-week antibiotic course following surgery was most effective. Our findings suggest that a subset of patients may benefit from longer courses of antibiotics; however, further research is needed to confirm these findings.
Irene K. Sigmund, Marjan Wouthuyzen-Bakker, Tristan Ferry, Willem J. Metsemakers, Martin Clauss, Alex Soriano, Rihard Trebse, and Ricardo Sousa
J. Bone Joint Infect., 10, 139–142, https://doi.org/10.5194/jbji-10-139-2025, https://doi.org/10.5194/jbji-10-139-2025, 2025
Short summary
Short summary
This is a summary of our position paper on debridement, antimicrobial therapy, and implant retention (DAIR) procedures as a curative treatment strategy for acute periprosthetic hip and knee infections. It includes the defined indications as well as the contraindications of DAIR procedures when eradication/cure is intended, based on the currently available literature.
Irene K. Sigmund, Tristan Ferry, Ricardo Sousa, Alex Soriano, Willem J. Metsemakers, Martin Clauss, Rihard Trebse, and Marjan Wouthuyzen-Bakker
J. Bone Joint Infect., 10, 101–138, https://doi.org/10.5194/jbji-10-101-2025, https://doi.org/10.5194/jbji-10-101-2025, 2025
Short summary
Short summary
In this paper, we discuss the most relevant factors influencing the outcome and define indications, contraindications, and risk factors of a DAIR procedure based on the currently available literature. Furthermore, we discuss the surgical technique in combination with systemic antimicrobial therapy in patients undergoing a DAIR procedure.
Said El Zein, Elie F. Berbari, Allison M. LeMahieu, Anil Jagtiani, Parham Sendi, Abinash Virk, Mark E. Morrey, and Aaron J. Tande
J. Bone Joint Infect., 9, 107–115, https://doi.org/10.5194/jbji-9-107-2024, https://doi.org/10.5194/jbji-9-107-2024, 2024
Short summary
Short summary
Our study investigated olecranon septic bursitis treatment, focusing on postsurgical antibiotic use. Analyzing 22 years of Mayo Clinic data, we found that smoking and not administering antibiotics following surgery led to poorer outcomes. A 3-week antibiotic course following surgery was most effective. Our findings suggest that a subset of patients may benefit from longer courses of antibiotics; however, further research is needed to confirm these findings.
Céline Dupieux, Ghislaine Descours, Paul Verhoeven, Florence Grattard, Yvonne Benito, François Vandenesch, Céline Cazorla, Tristan Ferry, Sébastien Lustig, Bertrand Boyer, Sandrine Boisset, Anne Carricajo, Frédéric Laurent, and PIRLA investigator group
J. Bone Joint Infect., 9, 37–48, https://doi.org/10.5194/jbji-9-37-2024, https://doi.org/10.5194/jbji-9-37-2024, 2024
Short summary
Short summary
We define an algorithm to optimize bone and joint infection diagnosis in adults on synovial fluid samples. This prospective multi-center study included a large number of synovial fluids and compared the performance of classical culture on different media, inoculation of synovial fluid in blood culture bottles, and broad-range and specific PCR. We proposed an algorithm associating culture onto three solid media and into blood culture bottles and 16S, Staphylococcus, and Streptococcus PCR.
Clément Javaux, Clémentine Daveau, Clotilde Bettinger, Mathieu Daurade, Céline Dupieux-Chabert, Fabien Craighero, Carine Fuchsmann, Philippe Céruse, Arnaud Gleizal, Nicolas Sigaux, Tristan Ferry, Florent Valour, and the Lyon BJI study group
J. Bone Joint Infect., 7, 127–136, https://doi.org/10.5194/jbji-7-127-2022, https://doi.org/10.5194/jbji-7-127-2022, 2022
Short summary
Short summary
We describe 48 osteocutaneous-flap-related osteomyelitis cases, mostly presenting with early, local signs of infection and/or bone exposure. Main pathogens were Gram-negative bacilli, streptococci, S. aureus, enterococci, and anaerobes, justifying a broad-spectrum empirical antimicrobial therapy. Despite surgery and a 3-month antimicrobial therapy, a 50 % failure rate was recorded, associated with a delayed infectious disease specialist referral and advocating for multidisciplinary management.
Truong-Thanh Pham, Eugénie Mabrut, Philippe Cochard, Paul Chardon, Hassan Serrier, Florent Valour, Laure Huot, Michel Tod, Gilles Leboucher, Christian Chidiac, and Tristan Ferry
J. Bone Joint Infect., 6, 337–346, https://doi.org/10.5194/jbji-6-337-2021, https://doi.org/10.5194/jbji-6-337-2021, 2021
Short summary
Short summary
Costs related to off-label expensive antibiotics used to treat bone and joint infections (BJIs) in a referral centre in France were analysed in this cohort study. Despite the large increase in the number of patients treated with these antibiotics, the overall costs remained stable (approximately EUR 1 million) and were helped by the appearance of generic molecules at lower prices. Production of generic antibiotics at low cost is essential to limit the financial burden of the management of BJIs.
Agathe Becker, Louis Kreitmann, and Tristan Ferry
J. Bone Joint Infect., 6, 19–20, https://doi.org/10.5194/jbji-6-19-2020, https://doi.org/10.5194/jbji-6-19-2020, 2020
Cited articles
Becker, K., Heilmann, C., and Peters, G.: Coagulase-negative staphylococci,
Clin. Microbiol. Rev., 27, 870–926, https://doi.org/10.1128/cmr.00109-13, 2014.
Cano, E. J., Caflisch, K. M., Bollyky, P. L., Van Belleghem, J. D., Patel,
R., Fackler, J., Brownstein, M. J., Horne, B., Biswas, B., Henry, M.,
Malagon, F., Lewallen, D. G., and Suh, G. A.: Phage Therapy for
Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case
Report and In Vitro Characterization of Anti-biofilm Activity, Clin. Infect.
Dis., 73, e144–e151, https://doi.org/10.1093/cid/ciaa705, 2021.
Clarke, A. L., De Soir, S., and Jones, J. D.: The Safety and Efficacy of
Phage Therapy for Bone and Joint Infections: A Systematic Review,
Antibiotics (Basel), 9, 795, https://doi.org/10.3390/antibiotics9110795, 2020.
Dublanchet, A. and Bourne, S.: The epic of phage therapy, Can. J. Infect. Dis.
Med. Microbiol., 18, 15–18, https://doi.org/10.1155/2007/365761, 2007.
Ferry, T., Kolenda, C., Batailler, C., Gustave, C. A., Lustig, S., Malatray,
M., Fevre, C., Josse, J., Petitjean, C., Chidiac, C., Leboucher, G., and
Laurent, F.: Phage Therapy as Adjuvant to Conservative Surgery and
Antibiotics to Salvage Patients With Relapsing S. aureus Prosthetic Knee
Infection, Front Med (Lausanne), 7, 570572, https://doi.org/10.3389/fmed.2020.570572, 2020.
Ferry, T., Kolenda, C., Batailler, C., Gaillard, R., Gustave, C. A., Lustig,
S., Fevre, C., Petitjean, C., Leboucher, G., and Laurent, F.: Case Report:
Arthroscopic “Debridement Antibiotics and Implant Retention” With Local
Injection of Personalized Phage Therapy to Salvage a Relapsing Pseudomonas
Aeruginosa Prosthetic Knee Infection, Front Med (Lausanne), 8, 569159,
https://doi.org/10.3389/fmed.2021.569159, 2021.
Fischetti, V. A.: Bacteriophage lysins as effective antibacterials, Curr.
Opin. Microbiol., 11, 393–400, https://doi.org/10.1016/j.mib.2008.09.012, 2008.
Fischetti, V. A., Nelson, D., and Schuch, R.: Reinventing phage therapy: are
the parts greater than the sum?, Nat. Biotechnol., 24, 1508–1511,
https://doi.org/10.1038/nbt1206-1508, 2006.
Fowler Jr., V. G., Das, A. F., Lipka-Diamond, J., Schuch, R., Pomerantz,
R., Jáuregui-Peredo, L., Bressler, A., Evans, D., Moran, G. J., Rupp, M.
E., Wise, R., Corey, G. R., Zervos, M., Douglas, P. S., and Cassino, C.:
Exebacase for patients with Staphylococcus aureus bloodstream infection and
endocarditis, J. Clin. Invest., 130, 3750–3760, https://doi.org/10.1172/jci136577, 2020.
Karau, M., Schmidt-Malan, S., Mandrekar, J., Lehoux, D., Schuch, R., Cassino, C., and Patel, R.: Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis, J. Bone Joint Infect., 7, 169–175, https://doi.org/10.5194/jbji-7-169-2022, 2022.
Karau, M. J., Schmidt-Malan, S. M., Yan, Q., Greenwood-Quaintance, K. E.,
Mandrekar, J., Lehoux, D., Schuch, R., Cassino, C., and Patel, R.: Exebacase
in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone
in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats,
Antimicrob. Agents Chemother., 63, e01235-19, https://doi.org/10.1128/aac.01235-19, 2019.
Karau, M. J., Schmidt-Malan, S. M., Mandrekar, J., Lehoux, D., Schuch, R.,
Cassino, C., and Patel, R.: Activity of Lysin CF-296 Alone and in Addition
to Daptomycin in a Rat Model of Experimental Methicillin-Resistant
Staphylococcus aureus Osteomyelitis, Antimicrob. Agents Chemother., 65, 00117-21,
https://doi.org/10.1128/aac.00117-21, 2021.
Oechslin, F.: Resistance Development to Bacteriophages Occurring during
Bacteriophage Therapy, Viruses, 10, 351, https://doi.org/10.3390/v10070351, 2018.
Papadopoulos, A., Ribera, A., Mavrogenis, A. F., Rodriguez-Pardo, D.,
Bonnet, E., Salles, M. J., Dolores Del Toro, M., Nguyen, S.,
Blanco-García, A., Skaliczki, G., Soriano, A., Benito, N., Petersdorf,
S., Pasticci, M. B., Tattevin, P., Tufan, Z. K., Chan, M., O'Connell, N.,
Pantazis, N., Kyprianou, A., Pigrau, C., Megaloikonomos, P. D., Senneville,
E., Ariza, J., Papagelopoulos, P. J., and Giannitsioti, E.:
Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic
joint infections: Role of surgery and impact of colistin administration, Int.
J. Antimicrob. Agents, 53, 294–301, https://doi.org/10.1016/j.ijantimicag.2018.10.018, 2019.
Schoeffel, J., Wang, E. W., Gill, D., Frackler, J., Horne, B., Manson, T.,
and Doub, J. B.: Successful Use of Salvage Bacteriophage Therapy for a
Recalcitrant MRSA Knee and Hip Prosthetic Joint Infection, Pharmaceuticals
(Basel), 15, 177, https://doi.org/10.3390/ph15020177, 2022.
Schuch, R., Khan, B. K., Raz, A., Rotolo, J. A., and Wittekind, M.:
Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent,
Antimicrob. Agents Chemother., 61, 001117-21, https://doi.org/10.1128/aac.02666-16, 2017.
Tande, A. J. and Patel, R.: Prosthetic joint infection, Clin. Microbiol. Rev.,
27, 302–345, https://doi.org/10.1128/cmr.00111-13, 2014.
Vasoo, S., Chan, M., Sendi, P., and Berbari, E.: The Value of Ortho-ID Teams in Treating Bone and Joint Infections, J. Bone Joint Infect., 4, 295–299, https://doi.org/10.7150/jbji.41663, 2019.